IDO1 and neoplasm: The authors discovered that the NLG919 prodrug had reduced systemic toxicity and better inhibition of intratumoral IDO compared with free NLG919 and RGD‐free NLG919 prodrugs, due to improved tumor accumulation and controlled release of NLG919 (Figure 7c).